CDRH Provides Update On Philips June 2021 Recall, Maintains Recommendations Related To Potential Health Risks Of PE-PUR Foam, FDA Says That Testing And Analysis Philips Shared Are Inadequate To Fully Evaluate The Risks Posed To Users From Recalled Devices
Portfolio Pulse from Benzinga Newsdesk
The Center for Devices and Radiological Health (CDRH) has provided an update on Philips' June 2021 recall, maintaining its recommendations related to potential health risks of PE-PUR foam. The FDA states that the testing and analysis Philips shared are inadequate to fully evaluate the risks posed to users from recalled devices.
October 06, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Philips' June 2021 recall continues to face scrutiny from the CDRH and FDA, which could potentially impact the company's reputation and stock price.
The CDRH's continued warnings and the FDA's criticism of Philips' testing and analysis methods could negatively impact the company's reputation. This could lead to a decrease in consumer trust and potentially affect the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100